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Cardiac Lesions Induced by Chemicals
by T. Balazs* and V. J. Ferranst
Chemically induced cardiomyopathies are frequently the consequences of a cardiac metabolic imbal-
ance brought about by exaggerated functional affects. The infarctlike lesions induced by adrenergic
beta-receptor stimulants and the vasodilating antihypertensives serve as examples of this phenomenon.
Direct cardiotoxic mechanisms not related to cardiovascular functional effects are responsible for another
class of toxic cardiomyopathy. An example ofthis is the cardiomyopathy produced by the anthracycline
antineoplastic agents. The pathogenesis, morphological changes and toxicologic features of these car-
diomyopathies are described with particular reference to their detection in preclinical toxicity studies.
Cardiotoxic chemicals have been identified in the
environment of industrial plants and among drugs,
pesticides, and even food additives. The character
of their effects varies from subtle functional alter-
ations to severe structural changes leading to heart
failure. Cardiac structural changes induced by
chemicals usually involve the myocardium itself.
The role of exogenous nonlipid chemicals in the
etiology of coronary heart disease is not known;
however, at least one chemical, carbon disulfide, is
considered, on the basis ofexperimental animal and
epidemiological studies, to enhance coronary
atherosclerosis (1).
At the beginning ofthis century, epinephrine was
shown to cause myocardial lesions. It was later
postulated that catecholamines play a role in the
etiology of noncoronarogenic ischemic heart dis-
ease (2). Those catecholamine analogs which are
adrenergic beta-receptor agonists cause focal
myocardial necroses due to hemodynamic changes
brought about by their pharmacological effects.
Such a mechanism is responsible for the car-
diotoxicity of a number of unrelated chemicals. A
true autonomous cardiotoxic effect is one which is
independent of the cardiovascular pharmacological
action. Among agents belonging to this category,
the anthracycline antineoplastic drugs are the most
thoroughly and most recently studied. The car-
diotoxic propensity of some compounds is en-
hanced by predisposing conditions, e.g., nutritional
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factors. This enhancement has been demonstrated
in studies with cobalt in rats, nutritional status most
likely played a role in the acute cardiomyopathy
that developed in beer drinkers consuming products
which contained cobalt salts added as a foam
stabilizer (3). Cardiac hypersensitivity reactions to
a few chemicals also have been described, usually
as part of allergic reactions involving several or-
gans.
Chemicals can induce persistent molecular
changes with functional consequences without
leading to morphologically detectable alterations.
For example, after cessation ofprolonged treatment
with propranolol, an adrenergic beta-receptor
blocker, supersensitivity develops to adrenergic
agonists (4, and Balazs et al., unpublished data).
This supersensitivity is attributable to an adaptive
increase in the population of beta receptors. The
increase develops during the blockade (5) but is de-
tectable only afterwards. Such an event serves as an
example ofthe development ofa solely biochemical
lesion that does not lead to a structural alteration.
Cardiomyopathies induced by chemicals (par-
ticularly by steroids) have been the subject of
heuristic research by Selye (6). In addition to his
classical monographs, other reviews have enriched
the literature on this subject (7, 8). In this communi-
cation we present a synopsis oftwo distinct types of
cardiomyopathy to exemplify the diversity of
pathogenetic, morphologic, and toxicologic
characteristics of chemically induced cardiac le-
sions. These examples also serve as prototypes of
the problems encountered in preclinical or-premar-
keting toxicology studies with new products. In
these studies, examinations using techniques of
October 1978 181clinical medicine, clinical pathology, and postmor-
tem pathology are carried outto detect the effects of
drugs on various organ systems, includingthe heart.
The limitations of these tests or, rather, the in-
adequacy of a standard test protocol for the detec-
tion ofspecific cardiotoxic effects, will be evident.
Cardiac Lesions Due to
Exaggerated Cardiovascular
Effects
Adrenergic beta-receptor agonists (isoproterenol,
metaproterenol, salbutamol, etc.) and the vas-
odilating antihypertensive agents (hydralazine,
diazoxide, minoxidil, etc.) produce myocardial ne-
croses in experimental animals (9-11). These le-
sions are consequences of the pharmacological ef-
fects of these drugs. The adrenergic drugs cause
these effects by their direct action on the cardiac
and vascular beta-receptors, whereas the an-
tihypertensives induce vasodilatation that results in
a reflex tachycardia via the adrenergic neuro-
transmitter. The adrenergic stimulation causes an
augmented transmembrane calcium influx, which
results in an increase in the rate and force of con-
traction (12). The energy and oxygen requirements
suddenly increase. The supply of energy from
high-energy phosphate bonds (adenosine triphos-
phate and creatine phosphate) is maintained as long
as aerobic glycolysis and mitochondrial oxidative
phosphorylation are unimpaired. Ifthe oxygen sup-
ply does not keep up with the demand, the high
energy stores become depleted. They are not well
maintained by anaerobic glycolysis. Both the ad-
renergic and antihypertensive agents cause
hypotension, which may result inhypoxemia. Then,
because ofthe tachycardia-induced decrease in the
duration of diastole (the cardiac perfusion period),
hypoxia develops in the least perfused area of the
heart, even if the coronary circulation is anatomi-
cally normal. Ifthe adrenergic stimulus and the cal-
cium influx continue, calcium accumulates in the
mitochondria and further impairs their function.
Hence the repletion of the energy stores will be
handicapped.
The least well perfused area of the heart is the
subendocardial zone of the left ventricle (particu-
larly the papillary muscles), since the coronary
pressure decreases and the tissue pressure in-
creases through the thick left ventricular wall; thus,
the perfusion pressure is the lowest in this zone.
The papillary muscles are further handicapped be-
cause of the large amount of mechanical work that
they carry out. For these reasons, the lesions in-
duced by adrenergic and antihypertensive agents
are most frequently located in the papillary muscles
and the subendocardial area of the left ventricle.
The extent of the lesions is dose-related, and with
sublethal doses the right ventricle and occasionally
the atria are also involved.
The lesion produced by these drugs is best elic-
ited by dosing on two consecutive days. In dogs
killed 24 hr thereafter, well demarcated grayish
areas, measuring 0.2 to 0.5 cm in diameter and 0.2
to 0.4 mm in depth, are seen on the papillary mus-
cles; similar or larger areas appear on the suben-
docardium of the left ventricle (Fig. 1). Microscop-
ically, the fibers show increased eosinophilia,
hypercontraction bands, granular swelling of the
sarcoplasm, and loss of nuclei. Inflammatory reac-
tion is mild. In dogs killed a few days later, focal
areas of myocardial cellular loss are the sites of
fibrocytic proliferation and histiocytic invasion.
The sequential development of the lesion has
been followed in rats given a single dose of iso-
proterenol (13-15). The earliest changes are seen in
the myofibrils. Irregular contraction bands with
rupture ofthe myofibrils develop within a few min-
utes. Mitochondrial changes, consisting of swelling
and the appearance of electron-dense deposits pre-
FIGURE 1. Subendocardial necroses in the left ventricle, most
prominent in the papillary muscles, induced in dog by the
administration of salbutamol, an adrenergic beta-receptor
agonist.
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FIGURE 2. Electron micrograph (courtesy of Dr. George Rona, Montreal) of left ventricular muscle cell from rat sacrificed 3 hr after
administration of isoproterenol. The myofibrils are hypercontracted. Lipid droplets (L) are present, and the mitochondria contain




183FIGURE 3. Myocardial necrosis with hypercontraction bands and cellular disruption is seen in left ventricular papillary muscle ofdog
sacrificed 24 hr after administration of minoxidil. Section of plastic-embedded tissue, 0.5 ,um thick, alkaline toluidine blue stain.
x300.
sumed to contain calcium, occur soon thereafter
(Fig. 2). Other organelles become displaced, and
then disintegration ofthe sarcolemma and of entire
fibers supervenes. By 8-24 hr after treatment, areas
ofhyaline necrosis and ofmyocytolysis are present
in association with macrophages and fibroblasts.
Similar ultrastructural changes have been found to
be produced by minoxidil, one of the vasodilating
antihypertensives (Figs. 3 and 4). The lesions pro-
duced by multiple dosing with any of the drugs
mentioned above are not more extensive than those
caused by one or two doses. Infact, the lesions heal
and may not recur during continuous dosing. A tol-
erance develops which lasts for a short period, even
after discontinuation ofthe dosing (16). A decrease
in the adrenergic receptor population may be sur-
mised to be involved in the mechanism ofthe toler-
ance. Such a phenomenon has been demonstrated
in erythrocyte membranes offrogs treated for 24 hr
with isoproterenol (17). The excessive calcium in-
flux into myocardium that follows the initial dose of
isoproterenol does not recur with multiple dosing
when the myocardium becomes tolerant to the car-
diotoxic effect (18).
Electrocardiographic examination is contributory
in the assessment of cardiac effects. Marked sinus
tachycardia, arrhythmias, and ST segment depres-
sion are seen in dogs soon after treatment with iso-
proterenol or diazoxide (11, 19) (Fig. 5). Ventricular
extrasystoles occurring 24 hr after treatment corre-
late with the presence of necrosis. ST segment de-
pression is the main electrocardiographic change
that occurs after development of the lesion in the
rat.
Serum aspartate aminotransferase and creatine
phosphokinase activities increase during the de-
velopment of the myocardial lesion induced by
isoproterenol. These activities are higher during the
first or second day of treatment than the-y are 24 hr
post-treatment, when values may return to normal
(20), indicating that the degenerative changes are
subsiding 24 hr after the end of dosing.
In afew instances, isoproterenol, hydralazine and
diazoxide also have been reported to produce
myocardial lesions in man (21-23). This is surpris-
ing, because multiples of the pharmacologic doses
are required, particularly in the case of isopro-
terenol and hydralazine, to cause lesions in animals.
However, several conditions (e.g., obesity, stress,
pretreatment with mineralocorticoids) that greatly
increase the susceptibility ofthe myocardium to the
cardiotoxicity of these agents have been identified
Environmental Health PerspectivesiP T Y~~~~~~~~~~~~~~~~~-i g
October 197 185 tg|PnDOE 25 PRAYS
tIU
5 SMY$ 24 1NO MTOSIN
FIGURE 5. Tachycardia and A-V nodal (5 sprays), ventricular (25
sprays) arrhythmia with ST segment depression in dog fol-
lowing intratracheal spraying with pressurized aerosol iso-
proterenol. The ventricular tachycardia 24 hr after dosing
suggests the presence of myocardial lesions. From Balazs et
al. (19) with permission of Academic Press.
in experimental animals (8, 24). These or other fac-
tors (e.g., anemia, preexisting cardiovascular dis-
ease) could have a sensitizing influence in man.
Propranolol, which blocks beta-adrenergic recep-
tors, protects against the lesions induced by iso-
proterenol, hydralazine, anddiazoxide in rats and in
dogs (II, 25). These findings are consistent with the
concept presented above on the mechanism of the
lesion. These antihypertensive drugs generally are
used for clinical treatment in combination with
propranolol. Verapamil, an agent which blocks cal-
cium influx, also provides protection against the ne-
crosis induced by isoproterenol and hydralazine in
the rat (Balazs, unpublished data), supporting the
role of calcium influx in the pathogenesis of this
lesion.
Cardiomyopathy Related to Direct
Cardiotoxicity of Chemicals
The problems encountered in the evaluation of
cardiotoxic effects of chemicals are illustrated by
the following description of the cardiomyopathy
produced by daunorubicin (DNR) and doxorubicin
(DXR) (Adriamycin), two highly effective an-
tineoplastic agents of the anthracycline type. The
therapeutic usefulness ofboth of these compounds
is limited by the development of acute and chronic
cardiotoxicity. Acute cardiotoxic effects consist of
hypotension, tachycardia, and various arrhythmias,
which develop within minutes after intravenous
administration (26, 27). Chronic toxicity is man-
ifested by the insidious onset of severe, often fatal
congestive heart failure; this may develop only after
several weeks or months of treatment, sometimes
after the course oftherapy has been completed. The
chronic cardiotoxicity is dose-dependent and gen-
erally occurs following a cumulative dose in excess
of 500 mg/M2 of body surface.
Anthracyclines induce complex biochemical ef-
fects on myocardium, including binding of an-
thracyclines to nuclear and mitochondrial DNA,
with subsequent inhibition ofthe synthesis ofRNA
and proteins (28), inhibition of Na-K-dependent
ATPase activity (29), inhibition of reactions utiliz-
ing coenzyme Q (30) and interference with other
aspects of mitochondrial functions (31), alterations
in calcium transport and in intracellular electrolyte
balance (32), chelation ofdivalent cations (32), and
promotion of lipid peroxidation by means of reac-
tions involving free radicals (33). The relative im-
portance ofthese effects in the pathogenesis of the
acute and the chronic cardiotoxicity remains to be
determined.
Acute Cardiotoxicity of Anthracyclines
Some ofthe acute effects of anthracyclines, i.e.,
the arrhythmias and the peripheral vascular effects,
may be consequences of drug-induced release of
histamine and catecholamines. Morphologic
changes related to the acute arrhythmias have not
been observed, although in chronic toxicity ofDXR
the specialized conducting cells of the rabbit heart
show lesions similar to those in ordinary myocar-
dium (34). Nucleolar segregation in the myocytes is
the only cardiac morphologic change that has been
found very soon (i.e., within minutes) after adminis-
tration of DXR (35, 36). This change is in accord
with observations showing that DXR and DNR
penetrate into nuclei, where they canbe detected by
the reddish fluorescence that they impart to nuclei
(37, 38), and that the nuclear binding involves inter-
calation ofthe drugs into nuclear DNA, thereby in-
hibiting nucleic acid and protein synthesis (28). The
long-term significance of nucleolar segregation is
unclear because this alteration disappears by 14 hr
afterDXR administration (35). Nuclearlesions have
been observed only in a small percentage ofcardiac
muscle cells in patients who died from chronic an-
thracycline toxicity (37, 39). These lesions consists
ofvarious degrees ofunraveling ofnuclear chroma-
tin fibers into the fine fibrils and filaments. Al-
though these changes are not specific, as they occur
in conditions otherthan anthracycline toxicity, they
can be reproduced in vitro (39) by incubating pieces
of myocardium with anthracycline-containing solu-
tions. These observations suggest that cumulative
damage to DNA in cardiac muscle cells (which can-
not reproduce themselves, thus diluting damage to
the genetic material) can result from the adminis-
tration ofrepeated doses ofanthracyclines, and that
Environmental Health Perspectives 186such damage cannot be repaired properly, thus
leading to interference with synthetic processes.
These effects may be of crucial importance in the
pathogenesis of anthracycline-induced car-
diomyopathy, because the half-life of contractile
proteins in myocardium is short (one to two weeks).
Chronic Cardiotoxicity of Anthracyclines
The morphologic changes in chronic anthracy-
cline cardiotoxicity are cardiac dilatation and, less
frequently, mural thrombosis; degeneration and at-
rophy ofcardiac muscle cells; and interstitial edema
and fibrosis. The first two of these changes are
similar to those seen in patients with congestive
(ventricular-dilated) cardiomyopathy. The degener-
ation ofcardiac muscle cells can assume two forms:
the first is characterized by loss of myofibrils, so
that by light microscopy the affected cells appear
pale-staining but nonvacuolated, and the second is
manifested by marked cytoplasmic vacuolization,
usually associated with myofibrillar loss. These
features are basically similar in humans (37, 39-41)
and in rat (42), mouse (35, 43) and rabbit (32, 44)
models of DXR cardiotoxicity. These changes are
related to total cumulative dose and also to the time
scheduling of the individual doses. Such changes
begin within 24 hrafterthe administration ofalarge,
single dose of DXR (35) but take several weeks or
months to develop when smaller, repeated doses
are given. No significant variations have beenfound
in the severity of morphologic changes demon-
strated by different patients or experimental ani-
mals in response to a given total cumulative dose
level. In histologic preparations the cytoplasmic
vacuolization is detected more easily than is the
myofibrillar loss. At the light microscopic level,
both of these changes are seen most clearly by
examining tissues fixed with glutaraldehyde, em-
bedded in plastic resins, sectioned at a thickness of
0.5-1.0 ,mm and stained with alkaline toluidine blue
(Fig. 6).
Electron microscopic studies (35-37, 39-44) have
shown that degeneration of cardiac muscle cells in
chronic anthracycline toxicity is a complex
phenomenon that involves the myofibrils, the nu-
clei, the T tubules, the sarcoplasmic reticulum, the
intercellular junctions, and the mitochondria. The
myofibrils show lysis ofthe myofilaments, changes
which account, at least in part, for the cellular at-
rophy. The vacuolization ofthe cytoplasm is mainly
due to pronounced swelling ofthe sarcoplasmic re-
ticulum (Fig. 7); accumulation oflipid and dilatation
of the transverse tubular system also contribute to
the vacuolated appearance. The intercellular junc-
tions undergo dissociation, with formation of
hemidesmosomes, intracytoplasmic junctions and
spherical microparticles. These three types of
change are also seen in myocardial degeneration of
other causes (45, 46). The mitochondria show
pleomorphism, decrease in size, alterations in the
density of the matrix, and concentric lamellae
(myelin figures) composed of electron-dense ma-
terial. Calcium-containing intramitochondrial inclu-
sions have not been demonstrated unequivocally in
DXR or DNR toxicity. The interstitial edema is in
accord with observations showing that cardiac tis-
sues in DXR toxicity have an increased content of
water, sodium, and calcium (32). The interstitial fi-
brosis is difficult to evaluate, because the cellular
atrophy exaggerates the prominence ofthe intersti-
tial connective tissue. Inflammatory reaction usu-
ally is absent or minimal and limited to the presence
of small numbers of macrophages. Endothelial
damage has been observed in rats (42) and mice (43)
but not in rabbits.
Pathogenesis of Cardiac Morphologic
Changes Induced by Anthracyclines
It seems likely that several different drug effects
are important in the pathogenesis of the changes
enumerated above. The myofibrillar loss probably
results from interference with protein synthesis; the
nuclear changes probably result from the binding of
DXR or DNR to nuclear DNA. The pathogenesis of
changes involving the membrane systems ofthe cell
is less clear. Such changes also may be related to
interference with normal synthesis and turnover of
proteins in membranes, but otherevidence suggests
that peroxidation ofmembrane lipids may be an im-
portant factor. DXR and DNR can initiate lipid
peroxidation by facilitating the transfer ofelectrons
from endogenous compounds such as NADPH to
oxygen, resulting in the formation of superoxides
that can decompose to hydroxy radicals, peroxy
radicals, and hydrogen peroxide. These, in turn,
can oxidize unsaturated fatty acids in membranes to
lipid peroxides (47).
The following three observations indicate that
lipid peroxidation may play a role in the
pathogenesis of anthracycline toxicity: (1) the ad-
ministration of very large doses of a-tocopherol
(vitamin E, a free radical scavenger) significantly
reduces the acute toxicity and mortality of DXR in
the mouse (47); (2) malondialdehyde, a product of
the peroxidation and subsequent decomposition of
unsaturated fatty acids, is readily detected in the
hearts of mice for 2-6 days after administration of
DXR, but not in the hearts of control mice or of
mice treated with both DXR and a-tocopherol (33);
and (3) ubiquinone, which acts as a free-radical
October 1978 187scavenger and as an antagonist to the inhibition by
anthracyclines of reactions involving coenzyme Q,
also has been reported to decrease the acute and
chronic toxicity of DXR (48).
It is worthy ofnote that exposure ofexperimental
animals to 100o oxygen at atmospheric pressure
and room temperature for less than one week in-
duces skeletal and cardiac muscle lesions (49) that
resemble in several respects (particularly in the
pronounced swelling ofthe sarcoplasmic reticulum)
those produced by anthracyclines. It is possible that
the oxygen-induced lesions are mediated by peroxi-
dation damage to membrane systems. Neverthe-
less, the cardiac morphologic changes in DXR and
DNR toxicity differ from those in radiation injury
and in deficiency ofselenium and vitamin E (Se-E),
two conditions in which free-radical damage and
peroxidation phenomena are thought to play a role
in the pathogenesis ofthe cardiac damage. In radia-
tion injury the initial cardiac damage is most promi-
nent in capillary endothelial cells, which become
edematous or necrotic; platelet and fibrin thrombi
are frequent. Severe interstitial fibrosis develops
subsequently, but at no time do the cardiac myo-
cytes show alterations similar to those in chronic
DXR toxicity (50). Comparison of the pathologic
changes produced by DXR and by Se-E deficiency
is of interest because selenium and vitamin E, in
conjunction with glutathione peroxidase, form an
antioxidant system that prevents the peroxidation
of membrane lipids. Cardiac lesions in Se-E defi-
ciency (51, 52) have been best characterized in the
pig, and consist of: multiple foci of necrosis, with
hyalinization or with hypercontraction bands and
mitochondrial swelling, disruption, and calcifica-
tion; intramyocardial hemorrhage ("mulberry
heart"); fibrinoid necrosis ofsmall intramural coro-
nary arteries; and capillary microthrombi composed
offibrin and platelets. Thus, it would seem from the
preceding comparisons that the cardiac mor-
phologic features of the toxicity produced by
peroxidation and free radical phenomena will vary
depending upon the nature and site ofrelease ofthe
offending compounds.
Predictive Value of Animal Tests
for Detection of Cardiac Lesions
The primary task of safety evaluation studies is
the detection of toxic effects on the various organ
systems. The complexity of this task is illustrated
by the failure ofdetection ofthe myocardial lesions
in preclinical studies with several ofthe compounds
FIGURE 6. Light micrograph ofleft ventricular myocardium ofrabbit with doxorubicin cardiotoxicity. Some cells (center) are greatly
vacuolated, whereas others (upperright) have apale cytoplasm and have lost most oftheirmyofibrils; the interstitium is edematous.
Section ofplastic-embedded tissue, 0.5 ,um thick, alkaline toluidine blue stain. x 1000.
Environmental Health Perspectives 188FIGURE 7. Electron micrograph ofvacuolated cardiac muscle cell from same tissue as in Fig 6. Vacuolization is mainly due to marked
dilatation of sarcoplasmic reticulum (SR). Myelin figures (MY) are present in moderate numbers. x5000.
described above. Although isoproterenol is the
model compound most widely used to produce
myocardial necrosis in experimental animals, this
effect was overlooked in the preclinical study (53).
Similarly, the preclinical tests failed to detect the
cardiotoxicity of anthracyclines, adrenergic beta-
receptor agonists, and vasodilating antihyperten-
sives. In the subacute study with isoproterenol, the
failure to detect these effects may have been due to
the fact that young rats were used, which are less
sensitive to this drug than are older ones. Morever,
the development of tolerance handicapped the de-
tection of lesions in these studies.
The cardiotoxicity of the adrenergic beta-
receptor agonist type of agent is best detected in
acute studies. Treatment oftwo consecutive days is
sufficient. The best time to record the electrocar-
diogram is during the peak of the pharmacological
effect and 24 hr after the end oftreatment. Animals
are killed 24 hr after the end of treatment for gross
and histological examinations. Examination of the
papillary muscles should not be neglected; special
staining techniques aid the detection of changes at
an early stage (54).
The cardiotoxicity ofanthracyclines was first dis-
covered in patients and only thereafter was repro-
duced in animals. It is conceivable that animals on a
daily treatment schedule with high doses died be-
cause of other toxic effects before heart lesions de-
veloped. The duration of tests was most likely too
short for the development of cardiac lesions in ani-
mals given low dose levels. The clinical dosage is an
intermittent one, e.g., once every 3 weeks. With
intermittent dosing, the cardiotoxicity seen in hu-
mans was reproduced in rabbits and in rats. This
finding indicates that the clinical dosage schedule
October 1978 189should influence the design of the animal experi-
ments. Additional testing in animals appears to be in
order when the clinical dose schedule differs from
that used in preclinical testing. Electrocardiograms
and measurements of serum enzymes of cardiac
origin are also of value in evaluating anthra-
cycline-induced cardiomyopathy in experimental
animals.
The scope and design of a toxicity study are
functions of the intended use of the chemical. The
conditions encountered in the utilization of the
chemical should be kept in mind, particularly with
food additives, household products, etc., which,
unlike pharmaceuticals, are not tested in humans
prior to marketing. Their safety evaluation is based
solely on data obtained from animals. Several con-
ditions, e.g., the nutritional factors described
above, can increase the susceptibility ofthe heart to
the cardiotoxic effects ofchemicals. The conditions
associated with the use of the chemical should be
incorporated in the toxicity study. For example,
when cobalt was considered as a beer additive, it
would have been prudent to test its cardiotoxicity in
animals kept on alcohol and also given diets defi-
cient in protein and thiamine, as test model condi-
tions for heavy beer drinkers.
In a lecture on the predictive value ofanimal tests
in relation to drugs affecting the cardiovascular
system in man, Black (55) said: "When we consider
animal tests as a means ofassessing these risks, we
must clearly distinguish between the predictions
which could have been made from animal tests and
the predictions which in fact were made before
human experimentation."
Generally, animal tests can provide reliable in-
formation on the potential cardiotoxicity of chemi-
cals. However, the cardiomyopathies described
above demonstrate that carefully designed testing is
necessary to improve the predictability of toxicity
studies for these effects.
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